22 Mar

Analysts Reiterate Incyte’s Target Price in March

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 2.58% for Incyte (INCY) based on the stock’s closing price on March 21.

Analysts revised the company’s target price upward from $85.63 in January to $89.33 in February and then reiterated that target price in March. The current consensus analyst recommendation for the stock is a “buy.”

Analysts Reiterate Incyte’s Target Price in March

Of the 21 analysts covering Incyte, five have given it “strong buys,” ten have given it “buys,” and six have given it “holds.” The highest target price estimate for the company is $111, and the lowest is $74.

On March 21, Incyte closed at $87.08, 0.89% higher than its previous closing price, 52.77% higher than its 52-week low of $57.00, and 2.97% lower than its 52-week high of $89.75. The company’s market cap is $18.55 billion.

Based on its closing price on March 21, Incyte has reported returns of 3.29% in the last week, 3.99% in the last month, and 35.51% in the last quarter. The company has reported returns of 28.40% in the last half year, 0.08% in the last year, and 36.94% year-to-date.

Revenue and EPS estimates

In its fourth quarter, Incyte reported revenue of $528.40 million, a YoY (year-over-year) rise of 18.97% and $42.68 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $0.40 but missed the consensus estimate by $0.09.

Analysts expect Incyte’s revenue to see YoY rises of 26.97% to $485.38 million in the first quarter, 18.06% to $497.66 million in the second quarter, 21.30% to $521.22 million in the third quarter, and 3.40% to $546.36 million in the fourth quarter of 2019. Analysts also expect Incyte’s non-GAAP EPS to see YoY rises of 4,150.0% to $0.41 in the first quarter, 90.06% to $0.49 in the second quarter, 45.95% to $0.55 in the third quarter, and 42.71% to $0.57 in the fourth quarter.

Analysts expect Incyte’s revenue to see YoY rises of 8.74% to $2.05 billion in 2019, 16.56% to $2.38 billion in 2020, and 17.30% to $2.80 billion in 2021. Analysts also expect Incyte’s non-GAAP EPS to see YoY rises of 89.71% to $1.97 in 2019, 46.64% to $2.89 in 2020, and 42.35% to $4.12 in 2021.

Next, we’ll discuss analysts’ recommendations and projections for Sorrento Therapeutics.

Latest articles

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.